Skip to main
ODTX

ODTX Stock Forecast & Price Target

ODTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Odyssey Therapeutics is a promising company with potential treatments for inflammatory and autoimmune diseases, including the successful results of OD-001 in a Phase 2a ulcerative colitis trial and the expected entrance of OD-002 into clinical trials. The company's focus on targeting inflammatory pathways and potential for combination therapies further supports the positive outlook, but potential risks and setbacks should be considered. The expertise and leadership of Dr. Natalie Dales, Chief of Research Operations and Portfolio Strategy, adds to the company's potential for success.

Bears say

Odyssey Therapeutics is facing tough competition in the market and while they have promising data from previous trials, their current pipeline is still in the clinical stage. The estimated high gross margin of 95% and potential FDA approval may seem positive, but as a financial analyst the focus is on potential future revenue and profits which may take a significant amount of time to materialize. Furthermore, the company's reliance on one physician-scientist for their expertise and patents could pose a risk in case of any unexpected events.

ODTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Odyssey Therapeutics Inc (ODTX) Forecast

Analysts have given ODTX a Buy based on their latest research and market trends.

According to 4 analysts, ODTX has a Buy consensus rating as of Sep 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Odyssey Therapeutics Inc (ODTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.